In order to bolster its pipeline, Johnson and Johnson (J&J) has entered into an agreement with Numab Therapeutics to acquire its subsidiary, Yellow Jersey Therapeutics, for the global rights to NM26, a Phase II-ready, first-in-class bispecific antibody targeting two clinically proven pathways in atopic dermatitis (AD). The all-cash transaction, worth approximately US$1.25 B, marks another move by J&J to help offset potential future losses from biosimilar competition of its blockbuster psoriasis drug Stelara. The Numab agreeement is J&J’s second deal driven by bispecific antibodies in recent weeks, following its US$850 M acquisition of Proteologix.